- Step Therapy Applies
- Orally administered anticancer medication.
- Quantity Limit: limit maximum 1 EA PER 1 day(s)
- Prior Authorization: Thyroid Carcinoma:
Thyroid Carcinoma
1. Initial Authorization
a. Caprelsa will be approved based on all of the following criteria:
(a) One of the following diagnosis:
i. Follicular Carcinoma
ii. Hurthle Cell Carcinoma
iii. Papillary Carcinoma
-AND-
(b) One of the following:
i. Unresectable recurrent
ii. Persistent locoregional disease
iii. Metastatic disease
-AND-
(c) One of the following:
i. Patient has symptomatic disease
ii. Patient has progressive disease
-AND-
(d) Disease is refractory to radioactive iodine treatment
Authorization will be issued for 12 months.
2. Reauthorization
a. Caprelsa will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Caprelsa therapy
Authorization will be issued for 12 months.
|